{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"190-709-420-900-784","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"190-709-420-900-784"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8901,"type":"PATENT","title":"University of Michigan Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14369,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8216,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
(a) administering an effective amount of a three-dimensional hydrogel comprising a biomolecular target molecule; and\n
(b) obtaining an antibody that specifically binds to the target molecule."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1 wherein the hydrogel comprises type I collagen, fibrin, or a mixture thereof."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 2 wherein the hydrogel comprises type I collagen."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 2 wherein the type I collagen, fibrin, or a mixture thereof is cross-linked."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1 wherein the biomolecular target molecule is a cell-surface protein."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 5 wherein the cell-surface protein is on the surface of a diseased cell."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6 wherein the diseased cell is a cancer cell, a fibrotic cell, an inflammatory cell, an immune cell or a cell participating in pathologic angiogenesis."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6 wherein the diseased cell is a cancer cell or a fibrotic cell."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1 wherein the biomolecular target molecule is α2 integrin, α-enolase, calnexin, CD44, filamin, vimentin, or fibrinogen."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1 further comprising a subtractive immunization procedure comprising\n
(a) administering an effective amount of a hydrogel comprising a healthy cell that is a counterpart to the cell associated with a disease, disorder or condition, to a host organism to elicit an antibody response; and\n
(b) delivering an immunosuppressive agent to the host organism."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 10 wherein the immunosuppressive agent is cyclophosphamide."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of producing an immunogen comprising\n
(a) obtaining a composition comprising a biomolecular target molecule;\n
(b) combining the composition comprising the biomolecular target molecule and a hydrogel-forming compound; and\n
(c) preparing a three-dimensional hydrogel comprising the composition comprising the biomolecular target molecule."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12 wherein the hydrogel comprises type I collagen, fibrin, or a mixture thereof."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 13 wherein the type I collagen, fibrin, or a mixture thereof is cross-linked."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12 wherein the biomolecular target molecule is a cell-surface protein."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 13 wherein the cell-surface protein is on the surface of a diseased cell."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 16 wherein the diseased cell is a cancer cell or a fibrotic cell."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 12 wherein the biomolecular target molecule is α2 integrin, α-enolase, calnexin, CD44, filamin, vimentin, or fibrinogen."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying an anti-cancer antibody product functional in vivo comprising\n
(a) contacting a protein capable of cross-linking to form a hydrogel with a cancer cell to produce a hydrogel comprising a cancer cell;\n
(b) incubating the hydrogel comprising a cancer cell; and\n
(c) exposing the hydrogel comprising a cancer cell to an anti-cancer antibody product candidate under conditions suitable for antigen-antibody product binding,\n
wherein binding between the anti-cancer antibody product candidate and the hydrogel comprising a cancer cell identifies the anti-cancer antibody product candidate as an anti-cancer antibody product."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 19 wherein the cross-linked protein is a cross-linked matrix protein."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 20 wherein the matrix protein is type I collagen, elastin, or a mixture thereof."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 21 wherein the matrix protein is type I collagen."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 19 wherein the protein is modified to produce an aldimine derivative of the protein and the aldimine derivative of the protein produces the cross-linked protein."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 23 wherein lysyl oxidase catalyzes the modification of the protein to produce the aldimine derivative of the protein."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 19 wherein the hydrogel further comprises an α2 integrin holoprotein."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 25 wherein the α2 integrin holoprotein is α2 β1 integrin."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 19 wherein the hydrogel further comprises the α2 subunit of α2 β1 integrin."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 19 wherein the antibody product is a polyclonal antibody, a monoclonal antibody, an antibody fragment, a hybrid antibody, a chimeric antibody, a CDR-grafted antibody, a single chain antibody, a single chain variable fragment antibody, a Fab antibody fragment, a Fab′ antibody fragment, a F(ab′)2 antibody fragment, a linear antibody, a bi-body, a tri-body, a tetrabody, a diabody, a peptibody, a bispecific antibody, a bispecific T-cell engaging (BiTE) antibody, or a chimeric antibody receptor."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 28 wherein the antibody product is a humanized or human antibody product."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["An antibody product produced by the method according to claim 19, wherein the antibody product is derived from the 4C3 monoclonal antibody."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The antibody product according to claim 28 wherein the antibody product is the 4C3 monoclonal antibody."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["A seeded hydrogel comprising\n
(a) a cross-linked protein; and\n
(b) an integrin protein."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The hydrogel according to claim 32 wherein the cross-linked protein is a matrix protein."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["The hydrogel according to claim 33 wherein the matrix protein is type I collagen, type III collagen, type IV collagen, fibrin, elastin, hyaluronic acid, laminin, or a mixture thereof."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["The hydrogel according to claim 32 wherein the integrin protein is α2 β1 integrin."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The hydrogel according to claim 32 wherein the integrin protein is the α2 subunit of α2 β1 integrin."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The seeded hydrogel according to claim 32 further comprising a cell exhibiting a disease, disorder or condition."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The seeded hydrogel according to claim 37 wherein the cell is a cancer cell, a fibrotic cell, an inflammatory cell, an immune cell, an endothelial cell, a pericyte, a smooth muscle cell or a mesenchymal stem cell."],"number":38,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}